Files and links (1)
Accepted (AM)Open Access (License Unspecified), Open
Journal article
Lectin-reactive Anti-alpha-Gal in Patients with Crohn's Disease: Correlation with Clinical Phenotypes
Inflammatory bowel diseases, v 19(13), pp 2796-2800
01 Dec 2013
PMID: 24185312
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Background:Patients with inflammatory bowel disease have higher proportions of immunoglobulin G (IgG) antibodies lacking N-galactose, also called agalactosyl IgG, in their serum. Such agalactosyl IgGs have been associated with disease activity and the immunogenicity of biologics. The aim was to describe the relationship between circulating levels of a subset of agalactosyl IgGs (anti--Gal) and Crohn's disease (CD) phenotypes.Methods:Prospectively collected serum samples of a well-characterized cohort of patients with inflammatory bowel disease and controls were used. Serum anti--Gal levels were measured by a high-affinity enzyme-linked immunosorbent assay and referenced to a standard control.Results:Serum samples from 167 subjects were tested; 62 with CD, 76 with ulcerative colitis, and 29 controls. Agalactosyl anti--Gal levels were significantly higher in active CD than in active ulcerative colitis (P = 0.0043) or healthy controls (P < 0.0001). Among patients with CD, agalactosyl anti--Gal levels were significantly higher in those with a history of arthritis, than those without (P = 0.0002), but lower in those taking immunomodulators (P = 0.03). There was no correlation between agalactosyl anti--Gal levels and indices of Crohn's severity, including C-reactive protein levels or Harvey-Bradshaw index. Patients who were primary or secondary nonresponders to infliximab had similar agalactosyl anti--Gal levels to clinical responders.Conclusions:Patients with CD have greater amounts of agalactosylated anti--Gal antibodies in their serum, particularly in those with associated joint disease. This increase seems to be independent of indices of disease activity, but is influenced by immunomodulator use.
Metrics
Details
- Title
- Lectin-reactive Anti-alpha-Gal in Patients with Crohn's Disease: Correlation with Clinical Phenotypes
- Creators
- Parham Safaie - Beth Israel Deaconess Medical CenterMaggie Ham - Beth Israel Deaconess Medical CenterPeter Kuang - Drexel UniversityAnand S. Mehta - Drexel UniversityMengjun Wang - Drexel UniversityAdam S. Cheifetz - Beth Israel Deaconess Medical CenterSimon Robson - Beth Israel Deaconess Medical CenterDaryl Lau - Beth Israel Deaconess Med Ctr, Liver Dis Ctr, Boston, MA 02215 USATimothy M. Block - Drexel UniversityAlan C. Moss - Beth Israel Deaconess Medical Center
- Publication Details
- Inflammatory bowel diseases, v 19(13), pp 2796-2800
- Publisher
- Oxford Univ Press
- Number of pages
- 5
- Grant note
- CA136607; CA168856-01 / NCI from the National Cancer Institute (NCI) Commonwealth of Pennsylvania K23DK084338 / NIH; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA Hepatitis B Foundation R01CA120206 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) K23DK084338 / NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Microbiology and Immunology
- Web of Science ID
- WOS:000329360500010
- Scopus ID
- 2-s2.0-84893766455
- Other Identifier
- 991019167454804721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Gastroenterology & Hepatology